# DESCRIPTION

## FIELD OF THE INVENTION

- introduce phthalimide derivatives of non-steroidal anti-inflammatory and/or TNF-α modulators

## BASIS OF THE INVENTION

- define inflammation
- describe acute and chronic inflammation
- motivate use of medicinal substances to treat pain and fever
- introduce non-steroidal anti-inflammatory drugs (NSAIDs)
- describe mechanism of action of NSAIDs
- introduce COX-1 and COX-2 isoforms
- describe physiological role of COX-2
- motivate development of COX-2 selective NSAIDs
- describe limitations of COX-2 selective NSAIDs
- introduce neuroprotective action of NSAIDs
- describe relationship between NSAIDs and Alzheimer's disease
- describe adverse effects of NSAIDs
- introduce TNF-α as a key regulator of proinflammatory cytokines
- describe role of TNF-α in autoimmune diseases
- introduce thalidomide as a TNF-α inhibitor
- describe therapeutic potential of thalidomide analogues
- motivate development of new thalidomide analogues

## SUMMARY OF THE INVENTION

- introduce phthalimide derivatives of NSAIDs as a new therapeutic approach for treating chronic inflammatory diseases

## Where:

- define NSAID and W
- define X
- list substituents for W
- list options for X

## DETAILED DESCRIPTION OF THE INVENTION

- introduce phthalimide derivatives of NSAIDs
- describe synthesis of phthalimide derivatives
- illustrate synthetic route in Scheme 1
- describe alternative synthesis route in Scheme 2
- describe administration of phthalimide derivatives
- describe pharmaceutical compositions and formulations

## EXAMPLES

### Example 1

- synthesize compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)-
- describe synthesis stages

### Example 2

- synthesize compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)
- describe synthesis stages
- provide NMR spectra

### Example 3

- synthesize compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)
- describe synthesis stages
- provide NMR spectra
- provide IR spectrum

### Example 4

- synthesize compound 2-(3-benzoylphenyl)-N-(1,3-dioxy-1,3-dihydro-
- describe synthesis stages
- provide NMR and IR spectra

### Example 5

- synthesize compound 2
- synthesize intermediary compounds
- characterize final product

### Example 6

- synthesize compound 2
- synthesize intermediary compounds
- characterize final product

### Example 7

- synthesize compound 7.1
- synthesize compound 7.2
- characterize final products

## Tests of the Rat Paw Edema Incuded by Carrageenin Utilizing The Compounds of the Invention Obtained in Examples 1.3, 2.3, 3.3, 5.3 and 6.3

- evaluate anti-inflammatory activity

## Example 8

### Test of Paw Edema Induced by Carrageenin with Pre-Treatment with the Compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)-2-hydroxybenzamide (derivative from salicylic acid)

- evaluate anti-inflammatory activity

## Example 9

### Test of Paw Edema Induced by Carrageenin with pre-treatment with the compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl)-2-(4-isobutylphenl) propanamide

- evaluate anti-inflammatory activity

### Example 10

- evaluate anti-inflammatory activity

### Example 11

- evaluate anti-inflammatory activity

### Example 12

- evaluate anti-inflammatory activity

### Example 13

- evaluate gastric lesions
- describe treatment with compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl
- describe treatment with compound N-(1,3-dioxy-1,3-dihydro-2H-isoindol-2-yl
- describe treatment with compound 2-{2-[(2,6-dichlorophenyl) amine]phenyl}-N-(1,
- describe treatment with compound 2-{2-[(2-chloro-6-fluorophenyl) amine]-5-methylphen
- compare with standard anti-inflammatory drugs
- conclude safer compounds

### Example 14

- evaluate abdominal contortion test
- describe methodology
- report results

### Methodologies Used for the Pharmacological Tests

- describe rat paws edema induced by carrageenan
- describe gastric lesion test
- describe abdominal contortion test
- describe statistical analysis

